![](https://www.forbes.com.au/wp-content/uploads/2023/11/vivo.jpg?w=959)
This startup raised $38 million to fill one of the biggest gaps in drug discovery
Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials.
Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials.